Abstract: The present invention provides an antibody that binds to an NTCP, capable of inhibiting infection of human hepatocytes with hepatitis B virus (HBV) particles. The present invention also provides an antibody that binds to an NTCP, capable of inhibiting infection of human hepatocytes with hepatitis B virus (HBV) particles, the antibody having a reduced effect on bile acid transport by NTCP.

Abstract: Disclosed are: a composition and a method for the diagnosis and/or the treatment of a CSABP-related disease, the regulation of the proliferation of an RNA virus and the regulation of an RNA-metabolizing system, which targets a cyclosporin A-binding protein (CSABP); a method for the screening of a component that targets a CSABP; a composition and a method for the detection/inhibition of CsA, NS5B or cyclosphilin B by utilizing a CSABP; a promoter for a CSABP; a method for the screening of a substance capable of regulating the expression of a CSABP by utilizing the promoter; and a method for the determination of the occurrence or clinical stage of a CSABP-related disease.

Abstract: Disclosed are non-immunosuppressive cyclophilin-binding cyclosporins, e.g., of formula (I, Ia or II) as defined herein, having useful properties in the prevention of Hepatitis C infections.

Abstract: The present invention provides (i) a method for proliferating a hepatitis virus, the method including the steps of: infecting, with the hepatitis virus, cells packed into a lumen of a hollow fiber made of a permeabilized membrane; and culturing the cells or (ii) a method for proliferating a hepatitis virus, the method including the steps of: infecting cells with the hepatitis virus; packing the cells into a lumen of a hollow fiber made of a permeabilized membrane; and culturing the cells. This provides an experimental system for infecting in vitro culture cells with a hepatitis virus such as HBV or HCV and then proliferating the hepatitis virus.

Abstract: Disclosed are non-immunosuppressive cyclophilin-binding cyclosporins, e.g. of formula (I, Ia or II) as defined herein, having useful properties in the prevention or treatment of Hepatitis C infections.

Abstract: An objective of this invention is to clarify the sequence of the 3'-end site of HCV genome and to provide a new process for detecting HCV.A new sequence with a highly conserved 3'-end site of the HCV genome has been found. Using the said sequences, new process for detecting HCV, a process for inhibiting proliferation of HCV, etc. have been provided.

Abstract: Double-stranded DNA characterized by having sequences complementary to a single-stranded DNA which has a molecular size of about 2.67 Kb and is derived from mungbean yellow mosaic virus, and giving the restriction endonuclease cleavage map shown in FIG. 1 of the accompanying drawings; and double-stranded DNA characterized by having sequences complementary to a single-stranded DNA which has a molecular size of about 2.70 Kb and is derived from mungbean yellow mosaic virus, and giving the restriction endonuclease cleavage map shown in FIG. 2 of the accompanying drawings; and hybrid DNAs having the double-stranded DNAs inserted thereinto.

Abstract: Double-stranded DNA characterized by having sequences complementary to a single-stranded DNA which has a molecular size of about 2.67 Kb and is derived from mungbean yellow mosaic virus, and giving the restriction endonuclease cleavage map shown in FIG. 1 of the accompanying drawings; anddouble-stranded DNA characterized by having sequences complementary to a single-straned DNA which has a molecular size of about 2.70 Kb and is derived from mungbean yellow mosaic virus, and giving the restriction endonuclease cleavage map shown in FIG. 2 of the accompanying drawings; and hybrid DNAs having the double-stranded DNAs inserted thereinto.